Related Experiment Video

Updated: May 2, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

13.6K

G6PD Enzyme Deficiency in Neonatal Pathologic Hyperbilirubinemia in Yazd

M Pahlavanzadeh1, S Hekmatimoghaddam2, M Teremahi Ardestani3

  • 1Doctor of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.

Iranian Journal of Pediatric Hematology and Oncology
|February 28, 2014
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is prevalent in Iranian neonates with jaundice, with 18.1% affected. Early G6PD testing is recommended to prevent complications like hemolysis.

Area of Science:

  • Medical Genetics
  • Neonatology
  • Biochemistry

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects 7.5% globally, with 10-14.9% prevalence in Iran.
  • This genetic disorder is a significant public health concern, particularly in regions with high carrier rates.

Purpose of the Study:

  • To determine the frequency of G6PD deficiency in jaundiced neonates hospitalized in Yazd, Iran.
  • To assess the association between G6PD deficiency and the severity of neonatal jaundice.

Main Methods:

  • A cohort of 105 icteric neonates was evaluated in Yazd hospitals.
  • G6PD activity was measured using a photometric biochemical assay.
  • Statistical analysis included Student's t-test and Pearson's chi-squared test.

Main Results:

  • 18.1% of neonates (19 out of 105) exhibited G6PD deficiency, with a higher prevalence in boys (29.4%) than girls (7.4%).
  • Jaundice onset occurred within the first week of life in all cases.
  • G6PD-deficient neonates required exchange transfusion significantly more often (31.5%) compared to G6PD-sufficient neonates (4.6%).

Conclusions:

  • The frequency of G6PD deficiency among jaundiced neonates in Yazd is notably high.
  • Given the severity and increased need for intervention, screening all jaundiced neonates for G6PD is recommended.
  • Universal G6PD testing in neonates is advised to prevent severe complications such as favism and drug-induced hemolysis.
Abstract

Keywords:
BilirubinFavismGlucosephosphate Dehydrogenase DeficiencyJaundiceNeonatal

More Related Videos

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

7.1K
Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates06:10

Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates

Published on: August 23, 2022

2.2K

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
35
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
4.4K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220